Search results for "Immunogen"

showing 10 items of 226 documents

Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant.

2017

Fully synthetic MUC1 glycopeptide antitumor vaccines have a precisely specified structure and induce a targeted immune response without suppression of the immune response when using an immunogenic carrier protein. However, tumor-associated aberrantly glycosylated MUC1 glycopeptides are endogenous structures, “self-antigens”, that exhibit only low immunogenicity. To overcome this obstacle, a fully synthetic MUC1 glycopeptide antitumor vaccine was combined with poly(inosinic acid:cytidylic acid), poly(I:C), as a structurally defined Toll-like receptor 3 (TLR3)-activating adjuvant. This vaccine preparation elicited extraordinary titers of IgG antibodies which strongly bound human breast cancer…

0301 basic medicinemedicine.medical_treatmentchemical and pharmacologic phenomenaBiochemistryCancer Vaccines03 medical and health sciencesMice0302 clinical medicineImmune systemCancer immunotherapyAdjuvants ImmunologicDrug DiscoverymedicineAnimalsHumansGeneral Pharmacology Toxicology and PharmaceuticsMUC1PharmacologyVaccines SyntheticbiologyChemistryImmunogenicityOrganic ChemistryMucin-1GlycopeptidesDendritic CellsVirologyGlycopeptideToll-Like Receptor 3030104 developmental biologyPoly I-C030220 oncology & carcinogenesisTLR3biology.proteinMolecular MedicineAntibodyAdjuvantChemMedChem
researchProduct

Immunogenicity of TNF alpha inhibitors in rheumatology: many questions, enough answers?

2016

030203 arthritis & rheumatology0301 basic medicinemedicine.medical_specialtyTumor Necrosis Factor-alphabusiness.industryImmunologic FactorsImmunogenicityGeneral MedicineRheumatologyDrug levelsAntirheumatic Agents03 medical and health sciences030104 developmental biology0302 clinical medicineAntirheumatic AgentsRheumatic DiseasesInternal medicineImmunologyHumansImmunologic FactorsMedicinePharmacology (medical)Anti-TNF therapyTumor necrosis factor alphabusinessExpert Opinion on Drug Safety
researchProduct

The sharedneoantigen landscape of MSI cancers reflects immunoediting during tumor evolution

2019

AbstractThe immune system can recognize and attack cancer cells, especially those with a high load of mutation-inducedneoantigens. Suchneoantigens are particularly abundant in DNA mismatch repair (MMR)-deficient, microsatellite-unstable (MSI) cancers. MMR deficiency leads to insertion/deletion (indel) mutations at coding microsatellites (cMS) and toneoantigen-inducing translational frameshifts. The abundance of mutationalneoantigens renders MSI cancers sensitive to immune checkpoint blockade. However, the neoantigen landscape of MMR-deficient cancers has not yet been systematically mapped. In the present study, we used a novel tool to monitorneoantigen-inducing indel mutations in MSI colore…

0303 health sciencesImmunogenicityfood and beveragesBiologydigestive system diseasesImmune checkpoint3. Good health03 medical and health sciences0302 clinical medicineImmune systemImmunoediting030220 oncology & carcinogenesisCancer cellCancer researchDNA mismatch repairIndelINDEL Mutation030304 developmental biology
researchProduct

Contribution of IL-17-producing {gamma}{delta} T cells to the efficacy of anticancer chemotherapy.

2011

IL-17 production by γδ T cells is required for tumor cell infiltration by IFN-γ–producing CD8+ T cells and inhibition of tumor growth in response to anthracyclines.

Adoptive cell transferMESH : AgedMESH : Equipment DesignCD8-Positive T-LymphocytesMESH: CatheterizationInterleukin-23MESH: Long-Term CareMice0302 clinical medicineMESH : CatheterizationT-Lymphocyte SubsetsMESH: NursingImmunology and Allergy[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyInterferon gammaMESH: Quality of Health CareMESH: Professional Review OrganizationsMESH: AgedMESH : Gels0303 health sciencesMice Inbred BALB CCell DeathInterleukin-17MESH : Methylene BlueMESH : Quality of Health CareReceptors Antigen T-Cell gamma-deltaChemotherapy regimenMESH: Transplantation Autologous3. Good healthMESH: Cosmetic TechniquesTreatment Outcomemedicine.anatomical_structureMESH : Cadaver[SDV.IMM]Life Sciences [q-bio]/ImmunologyImmunogenic cell deathSarcoma ExperimentalInterleukin 17MESH : DissectionMESH : Long-Term CareMESH: Nursing CareMESH: Adipose Tissuemedicine.drugSignal TransductionMESH : Transplantation Autologous[SDV.IMM] Life Sciences [q-bio]/ImmunologyMESH : Feasibility StudiesMESH: GelsT cellMESH : MaleImmunologyMESH: DissectionAntineoplastic AgentsBiologyMESH : NursingMESH : Adipose TissueArticleMESH : Facial Muscles03 medical and health sciencesInterferon-gammaLymphocytes Tumor-InfiltratingImmune systemAntigenCell Line TumorMESH: Patient Care PlanningmedicineMESH: CadaverAnimalsMESH : Patient Care Planning030304 developmental biologyMESH: Humansbusiness.industryMESH: Facial MusclesT-cell receptorMESH : HumansCorrectionMESH: MaleMice Inbred C57BLMESH : Cosmetic TechniquesDoxorubicinImmunologyCancer researchMESH : Nursing CareMESH : Professional Review OrganizationsbusinessMESH: Feasibility StudiesCD8030215 immunologyMESH: Methylene BlueMESH: Equipment Design
researchProduct

Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men.

1995

The immunogenicity, reactogenicity, and safety of an inactivated hepatitis A vaccine were assessed in anti-HIV positive homosexual men. Fourteen anti-HIV positive (group 1) and 20 anti-HIV negative (group 2) men received vaccine (containing 720 ELISA units of hepatitis A antigen per dose) intramuscularly at 0, 1, and 6 months. Twelve unvaccinated anti-HIV positive men (group 3) were included as controls to evaluate disease progression. Seroconversion (anti-hepatitis V virus (HAV ⩾20 mlU/ml) was higher in group 2 than group 1 at months 2 (100% vs. 73%) and 7 (l00%vs. 77%). Group 2 had higher antibody titres than group 1 at months 1 (201 vs. 92 mlU/ml) and 7 (1, 687 vs. 636 mlU/ml). The decli…

AdultCD4-Positive T-LymphocytesMaleViral Hepatitis VaccinesCellular immunityHepatitis A vaccineAcquired immunodeficiency syndrome (AIDS)VirologyHIV SeronegativityHIV SeropositivityMedicineHumansHepatovirusSeroconversionHomosexuality MaleAgedAcquired Immunodeficiency SyndromeHepatitis A VaccinesReactogenicitybusiness.industryImmunogenicityHepatitis AHepatitis AMiddle Agedmedicine.diseaseVirologyCD4 Lymphocyte CountInfectious DiseasesVaccines InactivatedConsumer Product SafetyViral diseasebusinessJournal of medical virology
researchProduct

Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants

2003

Abstract A live attenuated human rotavirus (HRV) vaccine, strain RIX4414, was tested sequentially in adults, previously infected toddlers, and previously uninfected infants. A single dose was given to adults and toddlers and found well tolerated. Next, a dose ranging (three different viral concentrations) safety and immunogenicity study was conducted in rotavirus IgA antibody negative infants (N=192), who received two doses of RIX4414 vaccine or placebo at 2 and 4 months of age. No side effects were seen after vaccination. Specifically, administration of RIX4414 vaccine was not temporally associated with fever, diarrhea, or increase in liver transaminases. Rotavirus IgA seroconversion range…

AdultDiarrheaMaleAdolescentDose-Response Relationship ImmunologicReoviridaeVaccines Attenuatedmedicine.disease_causeRotavirus InfectionsVirusFecesDouble-Blind MethodLiver Function TestsRotavirusmedicineHumansCloning MolecularSeroconversionGeneral VeterinaryGeneral Immunology and Microbiologybiologybusiness.industryImmunogenicityRotavirus VaccinesPublic Health Environmental and Occupational HealthInfantbiology.organism_classificationVirologyImmunoglobulin AVaccinationTiterDiarrheaInfectious DiseasesChild PreschoolImmunologyMolecular MedicineFemalemedicine.symptombusinessVaccine
researchProduct

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-lab…

2021

Abstract: Background: Efficacy of the nine-valent human papillomavirus (9vHPV; HPV types 6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16 & ndash;26 years of age. We present a phase 3 immunogenicity and safety study of the 9vHPV vaccine in women 27 & ndash;45 versus 16 & ndash;26 years of age. Methods: This international, open-label study (NCT03158220) was conducted in women 16 & ndash;45 years of age. Participants (16 & ndash;26 years, n = 570 and 27 & ndash;45 years, n = 642) received a three-dose 9vHPV vaccination regimen (day 1, month 2, month 6). Month 7 geometric mean titers (GMTs) and seroconversion percentages to anti-HPV 6/11/16/18/31/33/45/52/58 w…

AdultHuman papillomavirusmedicine.medical_specialtyAdolescentAntibodies ViralYoung Adult03 medical and health sciencesNine-valent human papillomavirus vaccineImmunogenicity Vaccine0302 clinical medicine030225 pediatricsInternal medicinemedicineHumansPapillomavirus Vaccines030212 general & internal medicineSeroconversionHPV prophylaxisAdverse effectAgedCervical cancerHuman papillomavirus 16Human papillomavirus 18General VeterinaryGeneral Immunology and Microbiologybusiness.industryPapillomavirus InfectionsAdult vaccinationPublic Health Environmental and Occupational Healthmedicine.diseaseVaccine efficacyConfidence interval3. Good healthVaccinationClinical trialPrecancerRegimenInfectious DiseasesCervical cancerMolecular MedicineFemaleHuman medicinebusinessVaccine
researchProduct

B and T cell immune responses elicited by the Comirnaty® COVID-19 vaccine in nursing home residents

2021

Objectives The immunogenicity of the Comirnaty® COVID-19 vaccine is understudied in elderly people with comorbidities. SARS-CoV-2-S-targeted antibody and T cell responses following full vaccination were assessed in nursing home residents. Methods Sixty nursing home residents (44 female; age, 53-100 years), of whom 10 had previously been diagnosed of COVID-19, and 18 healthy controls (15 female; age, 27-54 years) were recruited. Pre- and post-vaccination blood specimens were available for quantitation of total antibodies binding SARS-CoV-2 S protein and enumeration of SARS-CoV-2-S-reactive IFN-γ CD4+ and CD8+ T cells by flow cytometry. Results The seroconversion rate in presumably SARS-CoV-2…

AdultMale0301 basic medicineMicrobiology (medical)COVID-19 VaccinesSARS-CoV-2-S antibodiesT-LymphocytesT cell030106 microbiologyNursing home residentsAntibodies ViralFlow cytometryInterferon-gamma03 medical and health sciences0302 clinical medicineImmune systemComirnaty®COVID-19 vaccinemedicineHumans030212 general & internal medicineSeroconversionAgedAged 80 and overB-Lymphocytesbiologymedicine.diagnostic_testbusiness.industrySARS-CoV-2ImmunogenicityImmunityCOVID-19General MedicineMiddle AgedNursing HomesVaccinationInfectious Diseasesmedicine.anatomical_structureSARS-CoV-2-S T cellsSpike Glycoprotein CoronavirusImmunologybiology.proteinFemaleOriginal ArticleAntibodybusinessCD8Clinical Microbiology and Infection
researchProduct

Allele frequencies of +874T→A single nucleotide polymorphism at the first intron of interferon-γ gene in a group of Italian centenarians

2002

Ageing is characterized by a pro-inflammatory status which could contribute to the onset of major age-related diseases such as cardiovascular diseases, neurodegeneration, osteoarthritis and osteoporosis, and diabetes. Thus, it can be hypothesized that genetic variations in pro- or anti-inflammatory cytokines might influence successful ageing and longevity. We have studied the distribution of +874T--A interferon-gamma (IFN-gamma) polymorphisms in a large number of Italian centenarians to evaluate if the two alleles might be differently represented in people selected for longevity. DNA samples were obtained from 174 Italian centenarians (99 years old, 142 women and 32 men) and from 24860-year…

AdultMaleAgingmedia_common.quotation_subjectSingle-nucleotide polymorphismImmunogeneticsBiologyPolymorphism Single NucleotideBiochemistryInterferon-gammaEndocrinologyGene FrequencyGenetic variationGeneticsHumansAlleleMolecular BiologyAllele frequencyGeneAllelesAgedmedia_commonAged 80 and overGeneticsLongevityCell BiologyMiddle AgedIntronsItalyAgeingImmunologyFemaleExperimental Gerontology
researchProduct

Immunogenicity and reactogenicity of the Biken acellular pertussis vaccine in young adults

2000

Abstract To assess the reactogenicity and immunogenicity of the Biken acellular pertussis vaccine (Pa) following administration of a single vaccine dose to young adults with or without a history of prior pertussis immunization, 104 healthy, male and female adults without primary pertussis immunization were enrolled in Mainz (former West Germany; “not previously pertussis vaccinated”, N-PPV-group); in parallel, 103 adults with a history of having received ≥four doses of a combined diphtheria-, tetanus-toxoid, whole-cell pertussis vaccine (DTwP) were enrolled in Magdeburg (former East Germany; “previously pertussis-vaccinated”, PPV-group). Large areas of redness (>20 mm) were seen in 2.9%/1.0…

AdultMaleDiphtheria-Tetanus-acellular Pertussis VaccinesBordetella pertussisVaccines AcellularHumansMedicineVirulence Factors BordetellaYoung adultAdhesins BacterialWhooping coughPertussis VaccineReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityDiphtheriaPublic Health Environmental and Occupational HealthToxoidAntibody titerToxoidsmedicine.diseaseAntibodies BacterialHemagglutininsInfectious DiseasesImmunologyMolecular MedicinePertussis vaccineFemaleSafetybusinessmedicine.drugVaccine
researchProduct